Mostrar el registro sencillo del ítem

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

dc.contributor.authorVansteenkiste, Johan F.
dc.contributor.authorCho, Byoung Chul
dc.contributor.authorVanakesa, Tonu
dc.contributor.authorEsteban González, Emilio 
dc.date.accessioned2017-02-01T07:39:45Z
dc.date.available2017-02-01T07:39:45Z
dc.date.issued2016
dc.identifier.citationLancet Oncology, 17(6), p. 822-835 (2016); doi:10.1016/S1470-2045(16)00099-1
dc.identifier.issn1470-2045
dc.identifier.issn1474-5488
dc.identifier.urihttp://hdl.handle.net/10651/39536
dc.description.sponsorshipGlaxoSmithKline
dc.description.sponsorshipThis study was designed, funded, and interpreted by GlaxoSmithKline in cooperation with an international steering committee
dc.description.statementofresponsibilityVansteenkiste, JF; Cho, BC; Vanakesa, T; De Pas, T; Zielinski, M; Kim, MS; Jassem, J; Yoshimura, M; Dahabreh, J; Nakayama, H; Havel, L; Kondo, H; Mitsudomi, T; Zarogoulidis, K; Gladkov, OA; Udud, K; Tada, H; Hoffman, H; Bugge, A; Taylor, P; Gonzalez, EE; Liao, ML; He, JX; Pujol, JL; Louahed, J; Debois, M; Brichard, V; Debruyne, C; Therasse, P; Altorki, N.
dc.format.extentp. 822-835
dc.language.isoeng
dc.relation.ispartofLancet Oncology
dc.rights© 2016 Elsevier Ltd.
dc.sourceWOS:000377066400066
dc.titleEfficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
dc.typejournal article
dc.identifier.doi10.1016/S1470-2045(16)00099-1
dc.relation.publisherversionhttp://dx.doi.org/10.1016/S1470-2045(16)00099-1


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem